BioMarin Pharmaceutical (BMRN) Receiving Somewhat Positive Media Coverage, Analysis Finds
Media stories about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.796829788521 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Wedbush Weighs in on BioMarin Pharmaceutical Inc.’s FY2017 Earnings (BMRN) (americanbankingnews.com)
- Ultragenyx’s rhGUS Gets FDA Nod for Rare Genetic Disease – Yahoo Finance (finance.yahoo.com)
- In The Spotlight: Catalyst Pharmaceuticals – Markets Insider (markets.businessinsider.com)
- BioMarin Pharmaceutical Inc. (BMRN) Receives Neutral Rating from Wedbush (americanbankingnews.com)
- BioMarin Pharmaceutical is Now Oversold (BMRN) – Nasdaq (nasdaq.com)
BioMarin Pharmaceutical (NASDAQ:BMRN) traded up $0.32 during trading on Monday, hitting $82.88. The stock had a trading volume of 970,900 shares, compared to its average volume of 1,245,065. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. BioMarin Pharmaceutical has a 52 week low of $79.50 and a 52 week high of $100.51.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The company had revenue of $334.18 million for the quarter, compared to the consensus estimate of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. The company’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period last year, the business posted $0.02 EPS. equities analysts forecast that BioMarin Pharmaceutical will post -0.65 earnings per share for the current fiscal year.
Several research analysts have issued reports on the company. Wedbush reiterated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, November 15th. Deutsche Bank AG reiterated a “buy” rating and issued a $119.00 price objective (up previously from $118.00) on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. UBS AG reiterated a “neutral” rating and issued a $93.00 price objective (up previously from $92.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, August 3rd. Finally, Cowen and Company reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $111.55.
In other BioMarin Pharmaceutical news, EVP Robert Baffi sold 18,415 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the sale, the executive vice president now directly owns 129,083 shares in the company, valued at approximately $11,931,141.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $90.50, for a total value of $1,357,500.00. Following the sale, the insider now owns 141,422 shares in the company, valued at $12,798,691. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,686 shares of company stock worth $3,736,318. Company insiders own 1.85% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.